domingo, 29 de mayo de 2016

Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review. - PubMed - NCBI

Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review. - PubMed - NCBI



 2016 May 17;61:137-145. doi: 10.1016/j.ejca.2016.03.009. [Epub ahead of print]

Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.

Abstract

The presence of a germline BRCA1/2 mutation improves options for tailored risk-reducing strategies and treatment in both breast and ovarian cancer patients and their relatives. Currently, referral for germline BRCA1/2 mutation testing of women with epithelial ovarian cancer (EOC) varies widely, based on different criteria, such as age of onset, family history of breast and/or ovarian cancer and histological type of EOC. The overall probability of a germline BRCA1/2 mutation in women with EOC is above 10%, and a substantial part of the germline BRCA1/2 mutation carriers is missed when applying these criteria for referral. Therefore, we strongly recommend referral of all women with EOC for genetic counselling and DNA analysis.
Copyright © 2016 Elsevier Ltd. All rights reserved.

KEYWORDS:

BRCA mutation; Epithelial ovarian cancer; Genetic testing; Probability; Referral

PMID:
 
27209246
 
[PubMed - as supplied by publisher]

No hay comentarios:

Publicar un comentario